KPV

KPV is three amino acids long: lysine, proline and valine, the last three links of alpha-melanocyte-stimulating hormone (alpha-MSH). Interest in that tail end dates to 1989, when a fragment of it reduced chemically induced ear swelling in mice, and more so at higher doses [1]. The draw since then has been that it seems to keep the anti-inflammatory activity of the parent hormone while leaving out its effect on skin pigment [2].

On peptide menus it is sold for gut inflammation, skin conditions and wound healing, often next to BPC-157 and TB-500 and sometimes blended with them. All of the research behind those uses comes from cell lines, mice and pieces of donated skin. When FDA reviewed KPV in 2026 it found no study in which a person had taken it, by any route, and no human safety data [7].

Its legal position moved on October 28, 2026. An interim HHS policy now says HHS will not take enforcement action against state-licensed pharmacies and physicians that compound KPV acetate as a cream or an oral product, under conditions [8]. That changes where a person can get it. It adds nothing to what is known about whether it works or what it does to people.

The best-supported idea is that KPV enters gut-lining cells through PepT1, a transporter for small peptides that is switched on in the inflamed colon. Inside the cell, nanomolar amounts damped NF-kappaB, a central switch for inflammatory signaling, in human cell lines [3]. Mice missing a working melanocortin-1 receptor still responded, which suggests KPV does not rely entirely on the receptor that alpha-MSH itself uses [4].

Beyond that, the target is unsettled. FDA's 2026 review described the molecular targets behind KPV's effects as unknown [7]. A plausible route into cells and a measurable effect on inflammatory signaling in a dish leave open the question that matters to a buyer, which is what a capsule or cream does in a person.

The gut work is the most developed part. In a 2008 Emory study, KPV added to drinking water reduced colitis in two chemically induced mouse models [3]. A German group the same year reported earlier recovery and better weight regain in two other mouse colitis models, and every MC1R-mutant mouse in the treated group survived a colitis challenge [4]. These are consistent findings from serious labs, all in animals whose colitis was produced on purpose.

Skin is where the only formal request to compound it pointed: the withdrawn nomination asked for a 0.1% cream or gel, and FDA noted that none of the nine papers it cited studied KPV in humans [7]. One lab test used donated human skin and found that plain KPV did not pass through at detectable levels unless the skin was first punctured with microneedles or an electric current was applied [5]. A cream that does not cross the skin barrier would need some other explanation for any effect.

Weight is the newest claim. One 2026 paper reported that KPV cut fat build-up in a mouse fat-cell line by about 55% and slowed weight gain in mice on a high-fat diet [6]. That is a single study measuring less gain, not loss, and nobody has repeated it.

Grade D. The full study-by-study table, FDA's findings and the July 2026 advisory committee history are in our evidence review, linked from this page.

No human dose has been tested, so none is supported. Mouse studies dosed by body weight or dissolved KPV in drinking water, and neither converts into a person's daily amount. The figures on vendor sites and forums are guesses, and this page does not repeat them.

The HHS policy sets routes rather than doses. A compounded KPV product it covers must be topical or oral, contain KPV acetate as its only active ingredient, and come on a prescription written for one patient [8]. For oral products the pharmacy is expected to keep records showing the formulation reaches adequate levels in the human body, a hard bar for a peptide that nobody has measured in human blood. Injected and nasal KPV sit outside the policy.

Nobody knows the side-effect profile. FDA found no acute or repeat-dose toxicity studies and no human exposure data, and its safety-risk page says the agency lacks information on whether KPV would cause harm in people [9] [7]. An empty adverse-event database here reflects how little reporting exists for compounded products. It does not show the peptide is safe.

What the October 28, 2026 policy adds is a paper trail. A covered pharmacy must buy KPV acetate from an FDA-registered facility, with lab paperwork showing each batch was tested for identity, purity, bacterial toxins and microbes. The label must say the product is compounded and not for resale, and serious side effects and product defects go to MedWatch, FDA's reporting system [8]. The policy is interim, it adds nothing to the 503A Bulks List, and HHS can pull it back if problems emerge. Research-use-only KPV bought online carries none of those safeguards.